

2021 European Hematology Association Annual Meeting

TAKEDA ONCOLOGY
SPONSORED ABSTRACTS












Learn more at [takedaoncology.com](https://www.takedaoncology.com)



©2021 Millennium Pharmaceuticals, Inc. All rights reserved.



ONCOLOGY

ABSTRACT #	TITLE	SESSION	
CHRONIC MYELOID LEUKEMIA			
ABSTRACT S153	OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)	ORAL PRESENTATION Response, resistance and treatment-free remission in CML	
MYELODYSPLASTIC SYNDROMES			
ABSTRACT S166	Lower Residual Mutation Load Following Treatment with Pevonedistat + Azacitidine Versus Azacitidine Alone: Comparative Analysis of Study Arms in P-2001, A Randomized Phase 2 Trial	ORAL PRESENTATION Novel targets in MDS	
ABSTRACT EP934	Impact of Transformation to Acute Myeloid Leukemia (AML) on Overall Survival (OS) Among Patients (PTS) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the USA	POSTER SESSION Myelodysplastic Syndromes - Clinical	
ABSTRACT EP928	Dose Selection of Pevonedistat + Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia: A Model-Based Analysis	POSTER SESSION Myelodysplastic Syndromes - Clinical	
MULTIPLE MYELOMA			
ABSTRACT S184	Measurable Residual Disease (MRD) Evaluation During Ixazomib (IXA) Maintenance in Newly Diagnosed Multiple Myeloma (NDMM): A Large Analysis of 1280 Patients (PTS) Enrolled in TOURMALINE-MM3 and -MM4	ORAL PRESENTATION New treatment strategies for newly diagnosed multiple myeloma	
ABSTRACT EP963	Final Analysis of the Phase 3 TOURMALINE-MM1 Study Investigating Ixazomib + Lenalidomide-Dexamethasone (IRD) vs Placebo-RD (PRD) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (PTS)	POSTER SESSION Myeloma and other monoclonal gammopathies - Clinical	
ABSTRACT EP985	Real-World Duration of Treatment (DOT) with Lenalidomide-Dexamethasone (RD)-Based Regimens in Patients (PTS) with Relapsed/Refractory Multiple Myeloma (RRMM): Outcomes from the Global INSIGHT MM Study	POSTER SESSION Myeloma and other monoclonal gammopathies - Clinical	
ABSTRACT EP994	Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (MM) Outside of a Clinical Trial: Final Analysis of the 'Use via Early Access to Ixazomib' (UVEA IXA) Study	POSTER SESSION Myeloma and other monoclonal gammopathies - Clinical	
ABSTRACT EP1039	Multiple Myeloma Treatment Patterns and Outcomes in the Public and Private Healthcare Systems in Brazil: One Country, Two Worlds - MMYBRAVE Study	POSTER SESSION Myeloma and other monoclonal gammopathies - Clinical	
HODGKIN LYMPHOMA			
ABSTRACT S205	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III or IV Classical Hodgkin Lymphoma: A 5-Year Update of the Phase 3 ECHELON-1 Study (NCT01712490)	ORAL PRESENTATION Hodgkin lymphoma - Clinical	
ABSTRACT EP769	Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYAS) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 ECHELON-1 Study	POSTER SESSION Hodgkin lymphoma - Clinical	
NON-HODGKIN LYMPHOMA			
ABSTRACT EP506	ECHELON-2 (NCT01777152) 5-Year Results of a Randomised, Double-Blind, Phase 3 Study of Frontline Brentuximab Vedotin + CHP vs CHOP in Patients with CD30-Positive Peripheral T-Cell Lymphoma	POSTER SESSION Aggressive Non-Hodgkin lymphoma - Clinical	

Oral presentations and e-posters are available in the EHA Virtual Congress platform on Friday, June 11 at 9:00 a.m. CEST.

Learn more at [takedaoncology.com](https://www.takedaoncology.com)



©2021 Millennium Pharmaceuticals, Inc. All rights reserved.



ONCOLOGY